People with Down syndrome have a 90% to 95% lifetime risk of Alzheimer’s disease. Amyloid accumulation is almost inevitable by age 40, and baseline assessment is recommended by age 40 with annual follow-up.
Northwestern University researchers found that levetiracetam, an FDA-approved anti-seizure medication, prevents formation of toxic amyloid-beta 42 peptides in the brain, offering a potential strategy for early Alzheimer's prevention.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07416201 |
Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without Thymectomy |
RECRUITING |
